# Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement

> **NCT05877300** · PHASE1 · RECRUITING · sponsor: **Harvard Apparatus Regenerative Technology, Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Esophageal Diseases

## Interventions

- **COMBINATION_PRODUCT:** CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus
- **COMBINATION_PRODUCT:** CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy

## Key facts

- **NCT ID:** NCT05877300
- **Lead sponsor:** Harvard Apparatus Regenerative Technology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-13
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877300, "Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05877300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*